Project Grant R15HL188412
Award Date 8/1/26
Completion Date 5/31/29
Dollars Obligated $567K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Regents of the University of Michigan $2,257,845 under a Project Grant (R01HL180433) on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of a real-time, non-invasive micro-rheology technique to characterize aging thrombi using ultrasound-responsive nanodroplets. The nanodroplets phase-transition into microbubbles when exposed to focused ultrasound above a threshold amplitude—a...
- The National Heart Lung and Blood Institute awarded Regents of the University of Michigan $771,350 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an endovascular vortex ultrasound thrombolysis system for treatment of pulmonary embolism. The project will design, fabricate, and characterize a vortex ultrasound transducer integrated into a 9-French catheter to achieve rapid (under 30 minutes) and safe thrombolysis with minimal lytic agent and...
- The National Heart, Lung, and Blood Institute awarded the Scripps Research Institute $1,101,338 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer noncovalent antibody-enzyme thrombolytic complexes that function orthogonally to the natural hemostatic system. The project, R01HL184492, addresses limitations of current plasminogen activator therapies—including narrow therapeutic window, contraindications, and risks of neurotoxicity, bleeding, and...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,200 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial cell fate switches and dysfunction driven by fibrotic matrix remodeling. The research uses mouse models and an in vitro human microphysiological system of arteriole and venule-scale microvessels embedded within tunable stromal mimetic matrices to demonstrate how fibrotic physical cues...
- The National Heart, Lung, and Blood Institute awarded Lawrence Technological University $444,589 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop multiscale computational modeling for assessing shear-induced bleeding risk in blood-contacting medical devices. The research addresses device-induced complications in blood-contacting medical devices used to manage and treat heart conditions. The project develops physics-based computational models to...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $167,400 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop nanoparticle-mediated delivery of CRISPR-Cas9 gene editing for sickle cell disease treatment. The project focuses on advancing non-viral platforms for therapeutic gene editing of hematopoietic stem and progenitor cells. Current gene therapy approaches using ex vivo viral transduction or...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $1,026,853 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to define the molecular basis of thrombospondin-1-induced fibro-fatty diaphragm remodeling as a driver of obesity-associated respiratory dysfunction. The research investigates how diet-induced obesity promotes diaphragm weakness through fibro-adipogenic progenitor cell expansion and extracellular...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,971 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage 12-lipoxygenase signaling as a therapeutic target in heart failure with preserved ejection fraction (HFPEF). The research program establishes 12-lipoxygenase (12-LOX), an enzyme that converts arachidonic acid into bioactive lipid mediators, as a master regulator of HFPEF progression...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on the role of Toll-like Receptor-9 (TLR9) in type II epithelial cells and fibroblasts during influenza and Staphylococcus aureus coinfection. The research addresses the mechanism by which TLR9 expression in lung structural cells contributes to poor outcomes during influenza-bacterial...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $529,957 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode neutrophil membrane mechanisms in antiphospholipid syndrome (APS). The project investigates how gasdermin D (GSDMD) and myeloperoxidase-dependent lipid peroxidation drive neutrophil activation and thrombosis in APS, an incurable autoimmune disease and leading acquired cause of thrombosis. Research...